Australian Translational Medicinal Chemistry Facility

 

The ATMCF was established in 2012 at the Monash Institute of Pharmaceutical Sciences (MIPS) to provide researchers with a medicinal chemistry facility to support early stage medicinal chemistry-led drug discovery development. MIPS is a multi-disciplinary research institute encompassing the key skills in translational aspects of drug discovery, delivery and development. 

The ATMCF is accessible to non-commercial and commercial users, with costs dependent on the type of user and the specific arrangement (fee for service, collaboration, or another model).  ATMCF has both academic and commercial collaborators. Some examples of current projects include:

  • University of Western Australia, University of Sydney, University of Tasmania, University of Wollongong, Griffith University, Drug for Neglected Diseases initiative, University of Dundee, GSK (Tres Cantos), Swiss Tropical Health Research Institute, University of Heidelberg. This collaboration is discovering new drugs for human African trypanosomiasis ('Sleepin Sickness') and Chagas disease.

  • CSIRO and investigators at Monash University. This collaboration is developing new compounds with potential antibiotic activity effective against so-called 'superbugs'.

  • Walter and Eliza Hall Institute of Medical Research, CSIRO, St Vincent’s Institute of Medical Research. This collaboration is developing potent epigenetic modulators for the treatment of acute myeloid leukaemia.

  • Army Malaria Institute, Griffith University, University of Melbourne. Potent antimalarial compounds are being developed and are being profiled by the pharmaceutical giant GSK.

Contact:  Prof Jonathan Baell

Email:  jonathan.baell@monash.edu.au

Phone:  +61 03 9903 9044

Level 14, 330 Collins St

Melbourne 3000 VIC

Call

T: +61 (07) 3735 4433

©2019 Therapeutic Innovation Australia

Enabled by

NCRIS-PROVIDER-RGB-REV.png